-
公开(公告)号：EP0407544B1
公开(公告)日：1995-05-03
申请号：EP90902092.7
申请日：1989-12-28
CPC分类号： C12N9/6464 , A61K38/00 , C07K1/107 , C07K16/40 , C12Y304/21069 , G01N2405/04
摘要： A Ca2+ dependent monoclonal antibody that specifically binds to a specific twelve peptide sequence (E D Q V D P R L I D G K) in the activation region of the protein C. The antibody does not bind to activated protein C and can be used to inhibit activation of protein C by thrombin-thrombomodulin. The antibody can be isolated from cell culture or ascites fluid in large quantities by affinity chromatography with mild conditions using the peptide bound to an immobilized substrate. The antibody has a number of specific uses in isolation and characterization of protein C and as a model for the design of Ca2+ dependent antibodies for the isolation of other proteins, as a diagnostic, and as a therapeutic to prevent activation of protein C. The protein c can be naturally produced or produced by expression of the recombinant gene. Advantages of the antibody in purification of protein C include the specificity for protein C and not activated protein C, and the unique Ca2+-peptide binding specificity which allows the binding site to be protected when it is being immobilized on the chromatographic support. In vivo, the antibody has been demonstrated to inhibit tumor growth. The antibody can also be used to promote clotting in patients having high levels of Factor VIII inhibitors.
-
2.发明公开ANTIBODIES TO POLYPHOSPHATE DECREASE CLOT FORMATION, DECREASE INFLAMMATION, AND IMPROVE SURVIVAL 审中-公开多聚磷酸盐抗体减少肺栓塞形成，减少炎症并提高生存率
公开(公告)号：EP3182983A2
公开(公告)日：2017-06-28
申请号：EP15833798.0
申请日：2015-08-20
CPC分类号： C07K16/44 , A61K2039/505 , C07K2317/76 , G01N33/84 , G01N2800/56
摘要： Hypercoagulable and hyperinflammatory responses can lead to a variety of diseases including but not limited to disseminated intravascular coagulation in sepsis, consumptive coagulopathy in trauma, thrombosis in the postsurgical setting, acute respiratory distress syndrome in lung, and other diseases or conditions. Polyphosphate is accumulated by many infectious microorganisms and may be released by damaged infectious microorganisms. In addition, polyphosphate is found in many organs and is released from activated platelets and mast cells. Polyphosphates activate the intrinsic pathway of coagulation that also induces inflammation. Hypercoagulable and hyperinflammatory challenge are mediators contributing to endothelial dysfunction, organ failure and death, which occur in many pathological conditions. As such, polyphosphates can be targeted pharmacologically by inhibitors, such as anti-polyphosphate antibodies, as well as used as biomarkers for diagnosis, prognosis, and treatment response indicators that may be used to provide guidance for alterations in treatment plans.
摘要翻译： 高凝状态和高炎症反应可导致多种疾病，包括但不限于败血症中的弥散性血管内凝血，创伤中的消耗性凝血病，术后环境中的血栓形成，肺中的急性呼吸窘迫综合征以及其他疾病或病症。 多磷酸盐被许多传染性微生物积累，并且可能由受损的传染性微生物释放。 另外，多磷酸盐在许多器官中被发现并且从活化的血小板和肥大细胞释放。 聚磷酸酯激活也诱导炎症的凝固的内在途径。 高凝状态和过度炎症刺激是导致内皮功能障碍，器官衰竭和死亡的介质，其发生在许多病理条件下。 因此，多磷酸盐可以通过抑制剂（例如抗多磷酸盐抗体）在药理学上靶向，并且可以用作诊断，预后和治疗反应指标的生物标志物，其可以用于为治疗计划中的改变提供指导。
-
公开(公告)号：EP1218753A2
公开(公告)日：2002-07-03
申请号：EP00965455.9
申请日：2000-09-26
IPC分类号： G01N33/86
CPC分类号： G01N33/86 , G01N2405/04
摘要： An assay to assess thrombotic risk in which oxidized lipids comprising phospholipids are utilized as a membrane source in a clotting assay and the results compared to an assay in which unoxidized phospholipid is used as a membrane source in the presence and absence of activated protein C ('APC'). The assay can monitor for the presence of antibodies in the patient which interfere specifically with the anticoagulant function of APC in an oxidation dependent or independent manner. This can indicate the propensity of the patient to experience episodes of vein thrombosis or arterial thrombosis.
-
公开(公告)号：EP0407544A1
公开(公告)日：1991-01-16
申请号：EP90902092.0
申请日：1989-12-28
IPC分类号： G01N33 , A61K39 , C07K1 , C07K7 , C07K14 , C07K16 , C07K19 , C12N5 , C12N9 , C12N15 , C12P21 , A61K38 , C12R1
CPC分类号： C12N9/6464 , A61K38/00 , C07K1/107 , C07K16/40 , C12Y304/21069 , G01N2405/04
摘要： La présente invention se rapporte à un anticorps monoclonal dépendant de la Ca2+, qui se lie spécifiquement à une séquence de 12 peptides spécifiques (EDQVDPRLIDGK) dans la région d'activation de la protéine C. L'anticorps ne se lie pas à la protéine C activée et peut être utilisée pour inhiber l'activation par thrombine-thrombomoduline de la protéine C. L'anticorps peut être isolé d'une culture cellulaire ou d'un fluide ascitique en grandes quantités par chromatographie par affinité dans des conditions douces, grâce à l'utilisation du peptide lié à un substrat immobilisé. L'anticorps trouve un certain nombre d'usages spécifiques comme isolateur et agent de caractérisation de la protéine C et comme modèle pour la mise au point d'anticorps dépendant de la Ca2+ en vue d'isoler d'autres protéines, ainsi que comme agent diagnostique et comme agent thérapeutique pour empêcher l'activation de la protéine C. La protéine C peut être produite naturellement ou par expression du gène recombinant. Parmi les avantages de l'anticorps dans la purification de la protéine C, on trouve sa spécificité pour la protéine C et pour la protéine C non activée et sa spécificité de liaison Ca2+ peptide unique, qui permet de protéger le site de liaison lors de son immobilisation sur le support chromatographique. In vivo, l'anticorps s'est révélé être un inhibiteur de la croissance tumorale. L'anticorps peut également être utilisé pour promouvoir la coagulation chez des patients présentant des hauts niveaux d'inhibiteurs de Facteur VIII.
-
-
-
搜索结果
4 条记录 (耗时 0.011 秒)
